Search Result

Results for "

chronic rheumatoid arthritis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (2) Apoptosis (2) c-Myc (1) Caspase (1) COX (7) DNA/RNA Synthesis (1) Drug Derivative (1) Elastase (2) Epoxide Hydrolase (1) ERK (3) HSP (1) IKK (1) Integrin (2) Interleukin Related (5) Isotope-Labeled Compounds (3) JNK (2) NF-κB (1) NOD-like Receptor (NLR) (1) p38 MAPK (2) PDGFR (1) Phospholipase (1) Prostaglandin Receptor (1) Reference Standards (3) Syk (1)
By Research Areas:	Cancer (13) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (28) Metabolic Disease (1) Neurological Disease (4)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-108841

Raleukin 50+ Cited Publications Kineret; Anakinra	Interleukin Related	Inflammation/Immunology Cancer
Raleukin (AMG-719) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin significantly reduces neutrophil accumulation in blood vessels and brain infarct volume as well as improves motor coordination performance in ischemic stroke mice model. Anakinra can be used to study chronic inflammatory disorders like rheumatoid arthritis and cardiovascular recurrence post-myocardial infarction .

HY-15322

PRT062607 4 Publications Verification P505-15; PRT-2607; BIIB-057	Syk Apoptosis Caspase	Inflammation/Immunology Cancer
PRT062607 (P505-15; PRT-2607) is an orally active ATP-competitive Syk inhibitor with an IC₅₀ value of 1 nM, and exhibits at least 80-fold selectivity over other kinases. PRT062607 blocks B cell antigen receptor-mediated activation, Fcε receptor 1-mediated basophil degranulation and microglial phagocytosis, and induces caspase-dependent apoptosis and microglial death. PRT062607 inhibits tumor growth and peripheral nerve injury-induced mechanical allodynia, and prevents neuronal loss. PRT062607 can be used in research related to rheumatoid arthritis, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, neurodegenerative diseases and neuropathic pain .

HY-17474

Parecoxib 5 Publications Verification SC 69124	COX	Infection Neurological Disease Inflammation/Immunology Cancer
Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor that is permeable to the blood-brain barrier, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.

HY-103595

Epirizole Mepirizole; DA-398	Drug Derivative	Inflammation/Immunology
Epirizole (Mepirizole) is an orally active NSAID (nonsteroidal anti-inflammatory agent). Epirizole shows anti-inflammatory activity, and can be used in chronic rheumatoid arthritis research .

HY-17474A

Parecoxib Sodium 5 Publications Verification SC 69124A	COX	Infection Neurological Disease Inflammation/Immunology Cancer
Parecoxib Sodium (SC 69124A) is a highly selective and orally active COX-2 inhibitor that is permeable to the blood-brain barrier, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib Sodium can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.

HY-P99198

Fletikumab NNC 0109-0012	Interleukin Related	Inflammation/Immunology
Fletikumab (NNC0109-0012) is a monoclonal antibody targeting to IL-20. Fletikumab can be used for inflammation research, such as rheumatoid arthritis .

HY-120039A

(S)-MDL-101146	Elastase	Inflammation/Immunology
(S)-MDL-101146 is the S-isomer of MDL-101146. MDL-101146 is an orally active, competitive and reversible inhibitor against human neutrophil elastase (HNE) with a K_i value of 25 nM. MDL-101146 inhibits HNE-induced hemorrhage in hamsters. MDL-101146 is promising for research of emphysema, rheumatoid arthritis, chronic bronchitis, cystic fibrosis, adult respiratory distress syndrome and glomerulonephritis .

HY-P10935A

Amilo-5MER TFA 5-MP TFA	Amyloid-β Interleukin Related	Inflammation/Immunology
Amilo-5MER (5-MP) TFA is an orally active and selective Serum Amyloid A (SAA) inhibitor. Amilo-5MER TFA specifically inhibits the release of pro-inflammatory cytokines IL-6 and IL-1β from SAA-activated cells. Amilo-5MER TFA reduces chronic inflammation and relieves symptoms of diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and multiple sclerosis (MS). Amilo-5MER TFA is promising for research of autoimmune diseases and chronic inflammatory diseases .

HY-175288

αMβ2 integrin agonist-1	Integrin JNK ERK	Inflammation/Immunology Cancer
αMβ2 integrin agonist-1 (Compound 8) is a highly selective αMβ2 integrin agonist with anti-inflammatory activity (EC₅₀=1.4 nM). αMβ2 integrin agonist-1 activates integrin-mediated cell adhesion and JNK/ERK signaling. αMβ2 integrin agonist-1 induces tumor-associated macrophage repolarization and enhances antitumor T-cell immune responses. αMβ2 integrin agonist-1 is promising for research of cancers and chronic inflammatory diseases (e.g., pancreatic cancer, rheumatoid arthritis) .

HY-111135

IKK2-IN-3	IKK	Inflammation/Immunology Cancer
IKK2-IN-3 is an IKK2 inhibitor with an IC₅₀ value of 0.075 μM. IKK2-IN-3 can be used for the research of cancer, rheumatoid arthritis, chronic obstructive pulmonary disease (COPD) .

HY-120039

(R)-MDL-101146	Elastase	Inflammation/Immunology
(R)-MDL-101146 is the R-isomer of MDL-101146. MDL-101146 is an orally active, competitive and reversible inhibitor against human neutrophil elastase (HNE) with a K_i value of 25 nM. MDL-101146 inhibits HNE-induced hemorrhage in hamsters. MDL-101146 is promising for research of emphysema, rheumatoid arthritis, chronic bronchitis, cystic fibrosis, adult respiratory distress syndrome and glomerulonephritis .

HY-116099

ER-819762	Prostaglandin Receptor	Inflammation/Immunology
ER-819762 is an orally active, highly selective prostaglandin E₂ (PGE₂) EP₄ receptor antagonist with an EC₅₀ of 70 nM against human EP₄ receptor. ER-819762 can be used for rheumatoid arthritis research .

HY-P10935

Amilo-5MER 5-MP	Amyloid-β Interleukin Related	Inflammation/Immunology
Amilo-5MER (5-MP) is an orally active and selective Serum Amyloid A (SAA) inhibitor. Amilo-5MER specifically inhibits the release of pro-inflammatory cytokines IL-6 and IL-1β from SAA-activated cells. Amilo-5MER reduces chronic inflammation and relieves symptoms of diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and multiple sclerosis (MS). Amilo-5MER is promising for research of autoimmune diseases and chronic inflammatory diseases .

HY-175286

α4β1 antagonist-1	Integrin ERK	Inflammation/Immunology Cancer
α₄β₁ antagonist-1 (Compound 4) is a highly selective α₄β₁ integrin antagonist (IC₅₀=15 nM). α4β1 antagonist-1 inhibits integrin-mediated cell adhesion and ERK1/2 signaling activation. α₄β₁ antagonist-1 also exhibits partial agonism toward α_Mβ₂ integrin (EC₅₀=23 nM). α₄β₁ antagonist-1 is promising for research of chronic inflammatory diseases (e.g., rheumatoid arthritis, multiple sclerosis) and cancers .

HY-103595R

Epirizole (Standard) Mepirizole (Standard); DA-398 (Standard)	Reference Standards Others	Inflammation/Immunology
Epirizole (Standard) is the analytical standard of Epirizole. This product is intended for research and analytical applications. Epirizole (Mepirizole) is an orally active NSAID (nonsteroidal anti-inflammatory agent). Epirizole shows anti-inflammatory activity, and can be used in chronic rheumatoid arthritis research .

HY-17474AR

Parecoxib Sodium (Standard) SC 69124A (Standard)	Reference Standards COX	Inflammation/Immunology Cancer
Parecoxib (Sodium) (Standard) is the analytical standard of Parecoxib (Sodium). This product is intended for research and analytical applications. Parecoxib Sodium (SC 69124A) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib Sodium can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.

HY-17474R

Parecoxib (Standard) SC 69124 (Standard)	Reference Standards COX	Inflammation/Immunology Cancer
Parecoxib (Standard) is the analytical standard of Parecoxib. This product is intended for research and analytical applications. Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.

HY-173568

DJ-89	Epoxide Hydrolase	Inflammation/Immunology
DJ-89 (Compound 77) is a potent soluble epoxide hydrolase (sEH) inhibitor with an IC₅₀ value of 0.51 nM . DJ-89 inhibits sEH from hydrolyzing epoxyeicosatrienoic acids (EETs), reducing the production of pro-inflammatory substances. DJ-89 is promising for research of acute and chronic inflammatory diseases (such as rheumatoid arthritis) .

HY-175432

p38 MAPK-IN-9	p38 MAPK	Inflammation/Immunology
p38 MAPK-IN-9 (Compound 15) is an orally active and highly selective p38α mitogen-activated protein kinase (p38 MAPK) inhibitor with an IC₅₀ value of 9.6 nM. p38 MAPK-IN-9 is promising for research of inflammatory diseases such as rheumatoid arthritis, septic shock, and chronic obstructive pulmonary disease (COPD) .

HY-17474S

Parecoxib-d3 SC 69124-d₃	Isotope-Labeled Compounds COX	Inflammation/Immunology Cancer
Parecoxib-d3 is the deuterium labeled Parecoxib. Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.

HY-17474AS

Parecoxib-d5 sodium SC 69124A-d₅	Isotope-Labeled Compounds COX	Inflammation/Immunology Cancer
Parecoxib-d₅ sodium is the deuterium labeled Parecoxib sodium. Parecoxib Sodium (SC 69124A) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib Sodium can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo .

HY-17474S1

Parecoxib-d5 SC 69124-d₅	Isotope-Labeled Compounds COX	Inflammation/Immunology Cancer
Parecoxib-d₅ (SC 69124-d₅) is deuterium labeled Parecoxib. Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.

HY-160637

Lp-PLA2-IN-17	Phospholipase	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Lp-PLA2-IN-17 (Compound 39) is an inhibitor of Lp-PLA₂. Lp-PLA2-IN-17 can be used to study disorders involving the hydrolysis of oxidized lipids into two inflammatory substances with the participation of Lp-PLA₂ .

HY-P992023

APX002	Interleukin Related	Inflammation/Immunology
APX002 is an anti-IL-1β humanized monoclonal antibody that binds to IL-1β with an affinity of 1.99×10 ^?10M. APX002 blocks IL-1β receptor binding, inhibits IL-1β-induced downstream cell signaling and biological effects.APX002 can be used for the research of rheumatoid arthritis, diabetes, gout, cryopyrin-associated periodic syndrome, chronic obstructive pulmonary disorder, atherosclerosis, vasculitis .

HY-175433

p38 MAPK-IN-10	p38 MAPK	Inflammation/Immunology
p38 MAPK-IN-10 (Compound 4) is an orally active and potent p38 MAP kinase inhibitor (IC₅₀=570 nM). p38 MAPK-IN-10 is promising for research of chronic inflammatory diseases such as rheumatoid arthritis and Crohn’s disease .

HY-111165

SNX-7081	HSP NF-κB ERK JNK PDGFR c-Myc DNA/RNA Synthesis Apoptosis	Inflammation/Immunology Cancer
SNX-7081 is an Hsp90 inhibitor with K_i and IC₅₀ values of 26 nM and 44 nM, respectively. SNX-7081 blocks the nuclear translocation of NF-κB, inhibits the production of pro-inflammatory cytokines, attenuates the ERK/JNK and PDGF signaling pathways, and suppresses LPS (HY-D1056)-induced nitric oxide production. SNX-7081 inhibits DNA repair, induces G₂/M cell cycle arrest, and triggers apoptosis via downregulation of MYC/nucleolin and activation of Fas. SNX-7081 can be used in research related to rheumatoid arthritis and cancer .

HY-183889

p-Ethoxychrysoidin	NOD-like Receptor (NLR)	Neurological Disease Inflammation/Immunology
p-Ethoxychrysoidin is a benzotriazole-based NLRP3 inhibitor. p-Ethoxychrysoidin can be used in research on inflammatory diseases and neurodegenerative diseases .

Cat. No.	Product Name

HY-L210

Anti-Rheumatic Arthritis Compound Library	1,909 compounds
Rheumatoid Arthritis (RA) is a autoimmune disease characterized by persistent joint inflammation. The pathology of RA includes immune cell infiltration, synovial lining proliferation, pannus formation, and the destruction of joint cartilage and bone, which is highly disabling. Due to long-term chronic inflammation, RA not only severely affects the quality of life of patients but can also damage multiple organs, leading to lung diseases, cardiovascular diseases, and malignant tumors. The pathogenesis of RA is complex, involving genetic, environmental, and immune factors. With the advancement of high-throughput screening technology, screening for compounds targeting JAK, CCR, MEK, MMP targets may contribute to the development of more effective drugs against Rheumatoid Arthritis (RA). MCE has collected 1,909 small molecule compounds with definite or potential anti-rheumatoid arthritis activity. This library is of significant value for researching the anti-RA drugs.

Anti-Rheumatic Arthritis Compound Library

1,909 compounds

Rheumatoid Arthritis (RA) is a autoimmune disease characterized by persistent joint inflammation. The pathology of RA includes immune cell infiltration, synovial lining proliferation, pannus formation, and the destruction of joint cartilage and bone, which is highly disabling. Due to long-term chronic inflammation, RA not only severely affects the quality of life of patients but can also damage multiple organs, leading to lung diseases, cardiovascular diseases, and malignant tumors. The pathogenesis of RA is complex, involving genetic, environmental, and immune factors. With the advancement of high-throughput screening technology, screening for compounds targeting JAK, CCR, MEK, MMP targets may contribute to the development of more effective drugs against Rheumatoid Arthritis (RA).

MCE has collected 1,909 small molecule compounds with definite or potential anti-rheumatoid arthritis activity. This library is of significant value for researching the anti-RA drugs.

HY-L014

NF-κB Signaling Compound Library	1,699 compounds
Nuclear factor-κB (NF-κB)/Rel proteins include NF-κB2 p52/p100, NF-κB1 p50/p105, c-Rel, RelA/p65, and RelB. These proteins function as dimeric transcription factors that regulate the expression of genes and influence a broad range of biological processes including innate and adaptive immunity, inflammation, stress responses, B-cell development, and lymphoid organogenesis. NF-κB plays a key role in regulating the immune response to infection. In addition, activation of the NF-κB pathway is involved in the pathogenesis of chronic inflammatory diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel disease. Incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development. MCE owns a unique collection of 1,699 small molecule compounds that can be used in the research of NF-κB signaling pathway or high throughput screening (HTS) related drug discovery.

NF-κB Signaling Compound Library

1,699 compounds

Nuclear factor-κB (NF-κB)/Rel proteins include NF-κB2 p52/p100, NF-κB1 p50/p105, c-Rel, RelA/p65, and RelB. These proteins function as dimeric transcription factors that regulate the expression of genes and influence a broad range of biological processes including innate and adaptive immunity, inflammation, stress responses, B-cell development, and lymphoid organogenesis. NF-κB plays a key role in regulating the immune response to infection. In addition, activation of the NF-κB pathway is involved in the pathogenesis of chronic inflammatory diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel disease. Incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development.

MCE owns a unique collection of 1,699 small molecule compounds that can be used in the research of NF-κB signaling pathway or high throughput screening (HTS) related drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-P10935A

Amilo-5MER TFA 5-MP TFA	Amyloid-β Interleukin Related	Inflammation/Immunology
Amilo-5MER (5-MP) TFA is an orally active and selective Serum Amyloid A (SAA) inhibitor. Amilo-5MER TFA specifically inhibits the release of pro-inflammatory cytokines IL-6 and IL-1β from SAA-activated cells. Amilo-5MER TFA reduces chronic inflammation and relieves symptoms of diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and multiple sclerosis (MS). Amilo-5MER TFA is promising for research of autoimmune diseases and chronic inflammatory diseases .

HY-P10935

Amilo-5MER 5-MP	Amyloid-β Interleukin Related	Inflammation/Immunology
Amilo-5MER (5-MP) is an orally active and selective Serum Amyloid A (SAA) inhibitor. Amilo-5MER specifically inhibits the release of pro-inflammatory cytokines IL-6 and IL-1β from SAA-activated cells. Amilo-5MER reduces chronic inflammation and relieves symptoms of diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and multiple sclerosis (MS). Amilo-5MER is promising for research of autoimmune diseases and chronic inflammatory diseases .

Cat. No.	Product Name	Target	Research Area	Image

HY-108841

Raleukin 50+ Cited Publications Kineret; Anakinra	Interleukin Related	Inflammation/Immunology Cancer
Raleukin (AMG-719) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin significantly reduces neutrophil accumulation in blood vessels and brain infarct volume as well as improves motor coordination performance in ischemic stroke mice model. Anakinra can be used to study chronic inflammatory disorders like rheumatoid arthritis and cardiovascular recurrence post-myocardial infarction .

HY-P99198

Fletikumab NNC 0109-0012	Interleukin Related	Inflammation/Immunology
Fletikumab (NNC0109-0012) is a monoclonal antibody targeting to IL-20. Fletikumab can be used for inflammation research, such as rheumatoid arthritis .

HY-P991586

KB002	Inhibitory Antibodies	Inflammation/Immunology
KB002 is a humanized monoclonal antibody inhibitor targeting GM-CSF. KB002 has significant immune activity and can be used for asthma, rheumatoid arthritis and chronic Idiopathic thrombocytopenia purpura (ITP) research .

HY-P992023

APX002	Interleukin Related	Inflammation/Immunology
APX002 is an anti-IL-1β humanized monoclonal antibody that binds to IL-1β with an affinity of 1.99×10 ^?10M. APX002 blocks IL-1β receptor binding, inhibits IL-1β-induced downstream cell signaling and biological effects.APX002 can be used for the research of rheumatoid arthritis, diabetes, gout, cryopyrin-associated periodic syndrome, chronic obstructive pulmonary disorder, atherosclerosis, vasculitis .

Cat. No.	Product Name	Chemical Structure

HY-17474S

Parecoxib-d3
Parecoxib-d3 is the deuterium labeled Parecoxib. Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.

Parecoxib-d3

Parecoxib-d3 is the deuterium labeled Parecoxib. Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.

HY-17474AS

Parecoxib-d5 sodium
Parecoxib-d₅ sodium is the deuterium labeled Parecoxib sodium. Parecoxib Sodium (SC 69124A) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib Sodium can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo .

Parecoxib-d5 sodium

Parecoxib-d₅ sodium is the deuterium labeled Parecoxib sodium. Parecoxib Sodium (SC 69124A) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib Sodium can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo .

HY-17474S1

Parecoxib-d5
Parecoxib-d₅ (SC 69124-d₅) is deuterium labeled Parecoxib. Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.

Parecoxib-d5

Parecoxib-d₅ (SC 69124-d₅) is deuterium labeled Parecoxib. Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: